Compare Natera Inc. Common Stock (NTRA) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Global X Uranium ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Global X Uranium ETF trades at $34.56 (market cap $5.50B). The key difference: Natera Inc. Common Stock is far larger — about 10.4× Global X Uranium ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Global X Uranium ETF for 64 Days on average.
| NTRA | URA | |
|---|---|---|
Market Cap | $57.03B | $5.50B |
Volume | 1,131,157 | 3,413,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $425.64 | $61.81 |
52-Week Low | $179.42 | $35.54 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
URA (Global X Uranium ETF) trades at $37.38, down 0.9% with a bearish technical signal from moving averages. The ETF provides diversified exposure to uranium miners and nuclear energy companies amid growing global nuclear adoption. Recent news highlights nuclear energy's role in meeting AI power demand and government support for reactor development. Key holdings include Cameco (over 20%) and Sprott Physical Uranium Trust (nearly 6%).
Outlook remains mixed with strong long-term nuclear demand drivers offset by recent sector volatility. Investment opportunity lies in nuclear's capacity factor advantages and policy support, while risks include uranium price fluctuations and concentrated holdings. The ETF's 18.9% correction presents potential entry point for thematic investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
